Circulating biomarkers for prostate cancer

[1]  Rajiv Dhir,et al.  Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. , 2005, Cancer research.

[2]  C. Croce,et al.  Detection of hematogenous micrometastasis in patients with prostate cancer. , 1992, Cancer research.

[3]  J. Oesterling,et al.  Age-specific reference ranges for serum PSA. , 1996, The New England journal of medicine.

[4]  A. Lu,et al.  Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. , 2002, The Journal of urology.

[5]  Hartwig Huland,et al.  Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. , 2003, The Journal of urology.

[6]  R. Haba,et al.  Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. , 2005, The Journal of urology.

[7]  A. Chinnaiyan,et al.  Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. , 2005, Cancer research.

[8]  M. Brawer,et al.  Measurement of complexed PSA improves specificity for early detection of prostate cancer. , 1998, Urology.

[9]  Daniel S. Miller,et al.  The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer , 2000, Cancer.

[10]  H. Lilja,et al.  Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood. , 2007, Clinical biochemistry.

[11]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[12]  P. Walsh,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.

[13]  Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. , 1998, Cancer research.

[14]  P. Bunting,et al.  Screening for prostate cancer with prostate-specific antigen: beware the biases. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[15]  V. Reuter,et al.  Prostate-specific membrane antigen: present and future applications. , 2000, Urology.

[16]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[17]  J. Beiser,et al.  Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. , 1997, The Journal of urology.

[18]  N. Bander,et al.  Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. , 2003, The Journal of urology.

[19]  Debashis Ghosh,et al.  Autoantibody signatures in prostate cancer. , 2005, The New England journal of medicine.

[20]  Andrew J Vickers,et al.  Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Ronquist,et al.  Antiprostasome antibody titres in benign and malignant prostate disease. , 2005, Anticancer research.

[22]  M. Ploug,et al.  Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. , 2004, Clinical chemistry.

[23]  M. Benson,et al.  Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. , 1996, The Journal of urology.

[24]  D. Tindall,et al.  Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. , 1999, Urology.

[25]  M. Benson,et al.  Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. , 1994, Urology.

[26]  S. Loening,et al.  A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. , 2005, The Journal of urology.

[27]  H. Nielsen,et al.  Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. , 1999, Journal of the National Cancer Institute.

[28]  R. Vessella,et al.  Screening for prostatic carcinoma with prostate specific antigen: results of the second year. , 1993, The Journal of urology.

[29]  V. Bilim,et al.  Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  J. Richie,et al.  Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.

[31]  D. Tan,et al.  Interleukin-6 polymorphism is associated with more aggressive prostate cancer. , 2005, The Journal of urology.

[32]  A. Haese*,et al.  Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ‐confined from locally‐advanced prostate cancer in total PSA‐levels below 10 ng/ml , 2001, The Prostate.

[33]  J. Hugosson,et al.  Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. , 2000, Urology.

[34]  H. Klocker,et al.  Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. , 2003, The Journal of urology.

[35]  M. Kattan,et al.  Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy , 2007, International journal of cancer.

[36]  M. Kattan,et al.  Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. , 2005, The Journal of urology.

[37]  A. Haese*,et al.  Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. , 2002, The Journal of urology.

[38]  A. Haese*,et al.  Development and external validation of an extended repeat biopsy nomogram. , 2007, The Journal of urology.

[39]  S. Selman,et al.  Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. , 2000, Oncology reports.

[40]  G. Murphy,et al.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.

[41]  Hartwig Huland,et al.  Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. , 2007, Clinical chemistry.

[42]  S. Shariat,et al.  Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. , 2004, Urology.

[43]  J. Oesterling,et al.  Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. , 2000, The Journal of urology.

[44]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[45]  G. Murphy,et al.  Prostate-specific membrane antigen (PSMA): current benefits and future value. , 2000, Seminars in surgical oncology.

[46]  A. Gao,et al.  Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  N. Brünner,et al.  Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. , 1997, European journal of cancer.

[48]  T. Stamey,et al.  Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. , 2003, The Journal of urology.

[49]  M. Kattan,et al.  Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Kattan,et al.  Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. , 2003, Cancer research.

[51]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[52]  Hartwig Huland,et al.  Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA‐elevation in serum , 2006, International journal of cancer.

[53]  D. Chopin,et al.  Blood‐based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term follow‐up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy , 1999, International journal of cancer.

[54]  I. Fidler,et al.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. , 1990, Cancer research.

[55]  Stig Nordling,et al.  Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue , 2005, The Prostate.

[56]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[57]  H. Borchers,et al.  Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases. , 1999, Anticancer research.

[58]  Michael W Kattan,et al.  The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.